This company develops novel therapies for neurofibromatosis 2 related schwannomatosis (NF2) and related disorders. They are advancing an antibody drug conjugate targeting meningiomas and an AAV based gene therapy for vestibular schwannomas. The focus is on providing safe and effective treatment options where current standards of care are limited.
Funding
Funding not disclosed
Founders
Product
Problem
Neurofibromatosis type 2 (NF2) is a rare genetic disorder caused by mutations in the NF2 tumor suppressor gene, leading to the development of tumors such as schwannomas and meningiomas. There are currently no FDA-approved drugs for NF2, and the standard of care, including open craniotomy, has limitations due to tumor location and potential neurological deficits.
Solution
NF2 Therapeutics is developing targeted therapies to address the underlying genetic causes of Neurofibromatosis 2 related schwannomatosis (NF2) and sporadic meningiomas. The company's pipeline includes an antibody-drug conjugate (ADC) designed to target meningiomas, as well as an adeno-associated virus (AAV) based gene therapy intended for vestibular schwannomas in NF2 patients. These therapies aim to restore Merlin protein function, which is lost due to NF2 mutations, to regulate cellular processes and inhibit tumor growth.
Target Audience
The primary target audience includes patients diagnosed with Neurofibromatosis 2 (NF2) and sporadic meningiomas, as well as physicians and researchers specializing in neurofibromatosis and related disorders.
Features
- Antibody-drug conjugate (ADC) targeting meningiomas associated with NF2 and sporadic cases
- AAV-based gene therapy for vestibular schwannomas in NF2 patients
- Therapies designed to address the underlying genetic mutations in the NF2 gene
- Focus on restoring Merlin protein function to regulate cell growth and prevent tumor formation